Related Experiment Video
Updated: Jun 6, 2026
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Rovadicitinib: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|June 4, 2026
Summary
Rovadicitinib is a new JAK/ROCK inhibitor approved in China for myelofibrosis. This milestone marks the first approval for this JAK/ROCK inhibitor in treating PMF, PPV-MF, and PET-MF.
Area of Science:
- Pharmacology
- Oncology
- Drug Development
Background:
- Rovadicitinib is a novel small molecule inhibitor targeting Janus kinase (JAK) and Rho-associated coiled-coil-containing protein kinase (ROCK).
- It is under development by Chia Tai Tianqing Pharmaceutical Group for myeloproliferative neoplasms and inflammatory conditions.
- Targeted indications include primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), graft-versus-host disease (GVHD), and haemophagocytic lymphohistiocytosis (HLH).
Purpose of the Study:
- To summarize the key developmental milestones of rovadicitinib.
- To highlight the drug's journey leading to its first regulatory approval.
Main Methods:
- Review of preclinical and clinical development data.
- Analysis of regulatory submission and approval processes.
- Summary of key scientific and manufacturing achievements.
Main Results:
- Rovadicitinib (Anxu®) received its first approval in China on February 25, 2026.
- The approval is for the first-line treatment of adult patients with intermediate-2 or higher-risk PMF, PPV-MF, or PET-MF.
Conclusions:
- The approval of rovadicitinib represents a significant advancement in the treatment of myelofibrosis.
- This milestone underscores the successful development of a dual JAK/ROCK inhibitor for challenging hematological malignancies.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:02Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...